Royalty Pharma plc RPRX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.62B | 2.54B | 2.44B | 2.38B | 2.35B |
| Total Other Revenue | -- | -- | 1.00M | 1.00M | 1.00M |
| Total Revenue | 2.62B | 2.54B | 2.44B | 2.38B | 2.35B |
| Cost of Revenue | 5.52M | 105.97M | -366.18M | -295.84M | -154.91M |
| Gross Profit | 2.61B | 2.43B | 2.81B | 2.67B | 2.50B |
| SG&A Expenses | 674.42M | 639.85M | 722.20M | 677.11M | 555.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 931.23M | 984.46M | 797.30M | 833.27M | 802.19M |
| Operating Income | 1.69B | 1.55B | 1.64B | 1.54B | 1.55B |
| Income Before Tax | 1.17B | 1.35B | 1.36B | 1.32B | 1.30B |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.17K | 1.35K | 1.36K | 1.32K | 1.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -500.84M | -534.87M | -531.73M | -553.25M | -537.67M |
| Net Income | 671.45M | 811.00M | 825.29M | 769.95M | 763.96M |
| EBIT | 1.69B | 1.55B | 1.64B | 1.54B | 1.55B |
| EBITDA | 1.69B | 1.56B | 1.65B | 1.01B | 653.92M |
| EPS Basic | 1.42 | 1.76 | 1.79 | 1.67 | 1.64 |
| Normalized Basic EPS | 0.78 | 0.55 | 0.73 | 0.57 | 0.65 |
| EPS Diluted | 1.42 | 1.76 | 1.79 | 1.66 | 1.63 |
| Normalized Diluted EPS | 0.63 | 0.44 | 0.58 | 0.44 | 0.53 |
| Average Basic Shares Outstanding | 1.88B | 1.87B | 1.85B | 1.85B | 1.88B |
| Average Diluted Shares Outstanding | 2.23B | 2.23B | 2.23B | 2.26B | 2.29B |
| Dividend Per Share | 0.93 | 0.91 | 0.90 | 0.88 | 0.87 |
| Payout Ratio | 60.89% | 49.21% | 46.94% | 49.13% | 49.42% |